CD8A and cancer: Treatment of mouse CD8+ T cells with the pharmacological inhibitor GSKJ4 led to decreased expression of IFNγ and increased expression of the exhaustion marker TIM3, suggesting that higher UTX expression may underlie the more robust anti‐cancer T cell response in females.